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Abstract
Background: Proteolytic processing of the prion protein (PrPC) by endogenous proteases generates bioactive
membrane-bound and soluble fragments which may help to explain the pleiotropic roles of this protein in the
nervous system and in brain diseases. Shedding of almost full-length PrPC into the extracellular space by the
metalloprotease ADAM10 is of peculiar relevance since soluble PrP stimulates axonal outgrowth and is protective in
neurodegenerative conditions such as Alzheimer’s and prion disease. However, molecular determinates and
mechanisms regulating the shedding of PrP are entirely unknown.
Methods: We produced an antibody recognizing the neo-epitope of shed PrP generated by ADAM10 in biological
samples and used it to study structural and mechanistic aspects affecting the shedding. For this, we investigated
genetically modified cellular and murine models by biochemical and morphological approaches.
Results: We show that the novel antibody specifically detects shed PrP in cell culture supernatants and murine
brain. We demonstrate that ADAM10 is the exclusive sheddase of PrPC in the nervous system and reveal that the
glycosylation state and type of membrane-anchorage of PrPC severely affect its shedding. Furthermore, we provide
evidence that PrP shedding can be modulated by pharmacological inhibition and stimulation and present data
suggesting that shedding is a relevant part of a compensatory network ensuring PrPC homeostasis of the cell.
Conclusions: With the new antibody, our study introduces a new tool to reliably investigate PrP-shedding. In
addition, this study provides novel and important insight into the regulation of this cleavage event, which is likely
to be relevant for diagnostic and therapeutic approaches even beyond neurodegeneration.
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Background
Proteolytic processing is an essential regulator of protein
function and differs from many other posttranslational
modifications by its irreversible character. As exempli-
fied decades ago in the case of prohormones (such as
the proopiomelanocortin [1]), differential or subsequent
cleavages by endogenous proteases produce fragments
with intrinsic biological functions, differing from the
ones of the larger precursors. This concept may also
help in understanding and explaining the biology of
other “multifunctional” proteins, i.e. proteins with more
than just one particular function ascribed to them.
One of these proteins is the cellular prion protein
(PrPC), for which a multitude of physiological functions
has been suggested in different tissues, cells and
experimental settings [2, 3], even though not in each case
without controversy or questionable reproducibility [4, 5].
For instance, PrPC has been linked to developmental
processes [6, 7], cell adhesion [8, 9], neurite outgrowth,
axon guidance and synapse formation [10–14], as well as
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to neuroprotection [15–17] and regulation of the
circadian rhythm [18]. Among the currently best
characterized functions are its contributions to myelin
maintenance [4, 19–21] and cellular homeostasis of
divalent ions [22, 23] as well as its involvement in
signaling events [24–26].
Too many functional implications for just one protein?
Not necessarily. While transient interactions of PrPC
with alternating binding partners in different cellular
locations may partially account for this functional
diversity [5, 27], so might its proteolytic processing [28].
In fact, different highly conserved cleavage events occur
constitutively on a relevant fraction of PrPC [29–31], yet
scientists are just starting to understand their biological
relevance.
In contrast to some of the suggested physiological func-
tions, the relevance of PrPC in neurodegenerative
proteinopathies is widely accepted. First and foremost, it is
the essential substrate for the process of templated
misfolding underlying fatal and transmissible prion
diseases, such as Creutzfeldt-Jakob disease in humans or
BSE in cattle [32–34]. Once having adopted its pathogenic
conformation (PrPSc), the prion protein is the key
component of the infectious particles termed prions
[32, 35–37]. Second, binding of toxic oligomeric
protein species, such as PrPSc (in prion diseases [38]),
Aβ (in Alzheimer’s disease [39–42]) or α-synuclein (in
Parkinson’s disease [43, 44]), to PrPC at the neuronal
surface results in neurotoxic signaling. As for the
physiological functions, increasing evidence suggests
that proteolytic cleavages also impact on these
pathogenic roles of the prion protein [28, 45, 46].
Here, we focus on the most membrane-proximate
cleavage of PrPC, i.e. its shedding from the neuronal
surface and release into the extracellular space by the
metalloprotease ADAM10 [47, 48]. This cleavage not
only regulates membrane levels of PrPC and, thus, PrPC-
related functions at the neuronal surface [28]. The
resulting soluble fragment, shed PrP, likely has intrinsic
functions as supported by studies using (recombinant)
anchorless analogues, that showed beneficial effects with
regard to axon outgrowth and synapse formation [13,
14] or neuroprotection [15, 49]. Focusing on
neurodegeneration, we have recently shown a significant
impact on the course of prion disease in mice by
conditional depletion of the sheddase ADAM10 [50, 51],
as have others by overexpression of exogenous
ADAM10 [52] or by transgenic expression of anchorless
versions of PrP [53, 54]. Moreover, by reducing
membrane-bound PrPC as a receptor and by producing
anchorless PrP, which can block and detoxify Aβ and
other harmful protein species in the extracellular space
[55–58], shedding may also have a protective role in
other, more frequent proteinopathies [45].
Surprisingly, shed PrP has recently been associated
with the development of specific tumours in the nervous
system, where it correlates with increased cancer cell
proliferation [59]. In addition, a recent report shows crit-
ical involvement of shed PrP in the neuropathogenesis
of HIV/AIDS by recruiting monocytes and aggravating
the inflammatory response and the associated cognitive
impairment [60].
Thus, given that shedding of PrPC might provide a
promising and potent target for therapy of various
pathological conditions, a deeper mechanistic
understanding and knowledge of factors influencing this
cleavage is required. Here, we first introduce and
characterize a novel antibody detecting shed PrP with
high specificity and sensitivity. Using this tool, we
investigate different structural (i.e. glycosylation state
and membrane anchorage) and mechanistic aspects in
vitro and in vivo for how they impact on this relevant
proteolytic event. Finally, we show that shedding is part




The following constructs were used for transient transfec-
tion of cells. Detailed descriptions of the constructs can be
found in the corresponding references: PrP-WT, PrPC
glycomutants PrP-G1, PrP-G2, PrP-G3 and anchor-
mutant PrPGPI-Thy1 [61], PrP-TM (PrP-CD4 [62, 63]). All
PrP constructs contained the 3F4 tag [64]. The N-
terminally truncated PrP-C1 construct was cloned from
the plasmid pcDNA3.1(+)/Zeo containing the murine
Prnp gene. The sequence coding for the N-terminal part
of PrPC (aa23–110) was deleted by use of the restriction
enzymes XbaI and HindIII and the resulting construct
(Δaa23–110; i.e. PrP-C1) was verified by DNA sequencing.
Antibody production
The sPrPG228 antibody for the specific detection of shed
PrP was generated by use of an anti-peptide approach
and the classical 87-day polyclonal protocol (Eurogentec,
Belgium). Briefly, based on the sequence information of
murine PrPC and previous determination of the cleavage
site for ADAM10 [47], a recombinant peptide NH2-C-
QAYYDG-COOH (in which G-COOH represents G228
as the new C-terminus of shed PrP exposed after cleav-
age (Fig. 1a)) was produced and N-terminally coupled to
Megathura crenulata keyhole limpet hemocyanin (KLH)
as carrier protein. This peptide was used as immunogen
and injected into rabbit at days 0, 14, 28 and 56 of the
programme. Bleedings were done at days 0, 38 and 66 to
investigate the success of the immunization process by
standardized ELISA tests. Animals were sacrificed and
final bleeds were obtained at day 87. Standardized
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quality measures and affinity purification were per-
formed at Eurogentec. Importantly, a second peptide
(NH2-C-KESQAYYDGRRS-COOH) mimicking the C-
terminus of fl-PrP (without the GPI anchor) was pro-
duced, coupled to a resin and served as a “negative con-
trol” to eliminate all antibodies from the polyclonal
serum that would otherwise bind to fl-PrP.
Rodent brain samples
Use of animal material in this study was in strict compli-
ance with the Guide for the Care and Use of Laboratory
Animals and ethics guidelines of the responsible local
authorities. Frozen forebrain samples from wild-type
C57BL/6, prion protein deficient (Prnp0/0 [65]), prion
protein overexpressing (tga20 [66]) mice as well as from
mice with conditional knockout of ADAM10 in
forebrain neurons (A10 cKO and wild-type littermate
controls [67]), with transgenic overexpression of domin-
ant negative ADAM10 (A10 d.n. and wild-type controls
[68]), with depletion of sortilin-1 (Sort1 KO and wild-
type controls [69]) or with a knock-in of 3F4-tagged
PrPC (PrP3F4KI and controls; both had a 192S4
background [70]), and from a rat and a rabbit were used
to prepare 10% (w/v) homogenates in RIPA buffer
(50 mM Tris-HCl pH 8, 150 mM NaCl, 1% NP-40, 0.5%
Na-Deoxycholate, 0.1% SDS) freshly supplemented with
Fig. 1 A new antibody directed against shed PrPC reveals important aspects of the ADAM10-mediated cleavage. a Shedding of murine PrPC by
ADAM10 at the plasma membrane (PM). The sPrPG228 Ab is directed against the C-terminus Gly228 exposed after release of shed PrP into the
extracellular space (ex). b Representative western blot of forebrain homogenates from Prnp0/0, wild-type control, ADAM10 cKO and tga20 mice,
first probed with sPrPG228 Ab and re-probed with POM2 against fl-PrP. An asterisk indicates position of signal from the initial detection of sPrP (in
controls and tga20 resulting in overexposure and blurred appearance when re-probed with POM2) and demonstrates a small shift in molecular
weight between sPrP and fl-PrP. c Western blot of tga20 brain shows that all PrPC glycoforms can be shed, though a clear preference exists for
the diglycosylated form. d Glycopattern analysis in three C57BL/6 mouse forebrains and quantification of glycoform proportions using sPrPG228
Ab and POM1 reveals a shift towards the diglycosylated form in sPrP compared to fl-PrP. e Western blot showing inhibitory effects of dominant-
negative ADAM10 in forebrains of transgenic mice (A10 d.n.) compared to controls on PrPC shedding. Premature/mature ADAM10 and C-terminal
fragments (CTF) confirm genotypes. Quantification shows relative levels of sPrP referred to fl-PrP signal (controls set to one; n = 4; p = 0.014). f, g
Representative analysis of precipitated supernatants and cell lysates of N2a cells treated with resveratrol (Resv), tamibarotene (Am80) or GI254023X (GI),
GM6001 and Batimastat. Resveratrol and Am80 increased shedding (f), whereas the ADAM10-specific inhibitor GI (f) and metalloprotease inhibitors
GM6001 and Batimastat (g) completely abolished it. f Re-probing the supernatant blot with POM2 shows an increase in fl-PrP released by other
mechanisms. g No obvious effect on fl-PrP (here deglycosylated (PNGase F)) or N1/C1 levels was detected upon treatment. h Glycopattern
comparison between sPrP (supernatants) and fl-PrP (lysates; n = 3) reveals predominance of shed diglycosylated PrP in N2a cells similar to
findings in mice (d). β-actin = loading control; “d, m, u” = di-, mono-, unglycosylated PrP
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Complete EDTA-free protease (PI) and PhosStop phos-
phatase inhibitor cocktails (Roche) on ice. Samples were
homogenized with 30 strokes using a dounce
homogenizer and incubated on ice for 20 min, shortly
vortexed and incubated for another 20 min before cen-
trifugation at 12,000 g at 4 °C for 12 min. Total protein
content was assessed by Bradford assay (BioRad). Super-
natants were either further processed for SDS-PAGE or
stored at − 80 °C.
Cell culture, transfection and treatments
Murine neuroblastoma cells (N2a) and mouse embry-
onic fibroblasts (MEF; [71]) were maintained at 37 °C
under an atmosphere of 5% CO2 in Dulbecco’s modified
Eagle’s medium (DMEM; Thermo Fisher Scientific) sup-
plemented with 10% fetal bovine serum (FBS; Thermo
Scientific Fisher). N2a PrP-KO cells were generated
using the TALEN approach and characterized in detail
before [72]. N2a PrP-KO cells were transfected using
Lipofectamine 2000 (Thermo Fisher Scientific) following
the manufacturer’s instructions. For stable overexpres-
sion of PrP3F4 in N2a PrP-KO (used for the glycopattern
analysis shown in Fig. 1h) cells were kept for 3 weeks in
selection media (Zeocin 400 μg/ml; Thermo Fisher Sci-
entific) and single resistant clones were selected for
amplification.
Treatments of cells were performed by adding the fol-
lowing compounds (and concentrations) to the cell cul-
ture media: Resveratrol (20 μM), Tamibarotene/Am80
(1 μM), GI254023X (3 μM), Tunicamycin (2.5 μg/ml),
Swainsonine (5 μg/ml), Leupeptin (200 μg/ml). All com-
pounds were purchased from Merck. These treatments
were carried out in 6-well plates with 1 ml OptiMEM
for 18 h overnight. In the case of Tunicamycin and
Swainsonine cells were pretreated for 8 h. Treatment
with GM6001 (25 μM) or Batimastat (10 μM) was for
10 h.
Treatment of cells with PI-PLC
Two days post-transfection cells (grown in 6-well plate
format) were incubated with 0.5 U/ml Phospholipase C
(PI-PLC; Sigma-Aldrich) in 1 ml OptiMEM for 2 h at
37 °C, 5% CO2 in order to cleave GPI-anchor structures
and release GPI-anchored proteins from the cellular sur-
face. Supernatants were subsequently harvested and fur-
ther processed while cells were lysed as described below.
PNGase F and Endo H digestion
For removal as well as for investigations on processing
and maturation of N-linked glycans attached to PrPC,
cell lysates and/or supernatants were digested with
either PNGase F or Endo H (New England Biolabs)
according to the manufacturer’s protocols.
Sample preparation, TCA precipitation, cell surface
biotinylation assay, SDS-PAGE and western blot analysis
N2a cells were washed with PBS and lysed with RIPA buf-
fer, incubated on ice for 15 min before centrifugation at
12,000 g for 12 min at 4 °C. The protein content of the
resulting supernatant was determined by Bradford assay.
Prior to SDS-PAGE, cell lysates or brain homogenates
(see above) were mixed with 4× loading buffer (including
β-mercaptoethanol) and denatured for 6 min at 96 °C.
For the analysis of cell culture supernatants, experiments
were carried out with serum-free media (OptiMEM). Su-
pernatants were precipitated with trichloroacetic acid
(TCA). For this, supernatants were collected and immedi-
ately incubated with already dissolved protease inhibitor
cocktail, cleared from dead cells and debris by mild centri-
fugations at 500 g and 5.000 g for 5 min each. 1/100 vol-
ume of 2% sodium deoxycholate (NaDOC) was then added
and each sample was shortly vortexed. After 30 min incu-
bation on ice, samples were mixed with 1/10 volume of
100% TCA and again incubated for 30 min on ice. After
centrifugation at 15,000 g for 15 min at 4 °C, the super-
natant was aspirated, and the air-dried pellet was dissolved
in 1× loading buffer and boiled for 6 min at 96 °C.
For labelling and purification of proteins at the cell
surface, a surface biotinylation assay was performed as
described earlier [50] prior to cell lysis.
For SDS-PAGE, denatured samples were loaded on either
precast Nu-PAGE 4–12% Bis-Tris protein gels (Thermo
Fisher Scientific) or self-made 10% or 12% SDS-gels. After
electrophoretic separation, proteins were transferred to
nitrocellulose membranes (BioRad) by wet-blotting and
membranes were subsequently blocked for 1 h with 5%
skimmed dry milk dissolved in TBS-T (containing 0.1%
Tween-20) and incubated with primary antibody diluted in
5% skimmed dry milk in TBS-T overnight at 4 °C on a
shaking platform. For detection of full length PrPC (fl-PrP),
mouse monoclonal antibodies POM1 (1 μg/ml), POM2 (0.
6 μg/ml) [73] or, in the case of the sortilin-1 knockout
mouse brains (Fig. 5j), SAF61 (0.2 μg/ml; Bertin Pharma)
were used. Proteolytically shed PrPC was detected with our
new rabbit polyclonal sPrPG228 antibody (0.2 μg/ml)
characterized in detail herein. Moreover, we used anti-
ADAM10 (0.4 μg/ml; abcam), anti-mouse β-amyloid
antibody for detection of sAPPα (1 μg/ml; BioLegend),
anti-actin antibody clone C4 (MAB1501, 1:1000; Merck)
and anti-Flotillin-1 clone 18 (0.25 μg/ml; BD Biosciences).
Membranes were subsequently washed with TBS-T and in-
cubated for 1 h with respective HRP-conjugated secondary
antibodies and subsequently washed 6× with TBS-T. After
incubation with Pierce ECL Pico or Super Signal West
Femto substrate (Thermo Fisher Scientific), chemilumines-
cence was detected with a ChemiDoc imaging station
(BioRad) and densitometrically quantified using Image
Studio Lite software version 5.2 (LI-COR).
Linsenmeier et al. Molecular Neurodegeneration  (2018) 13:18 Page 4 of 17
Immunofluorescence staining of surface proteins and
microscopy
N2a cells were grown on glass coverslips. After washing
with PBS, living cells were incubated for 20 min on ice
(to avoid endocytosis) with the primary antibody dis-
solved in 2% BSA/PBS. Surface PrPC was detected with
POM1 antibody (10 μg/ml). After several washes with
PBS, cells were incubated with suitable secondary
antibodies for 20 min on ice, subsequently fixed in 4%
paraformaldehyde for 20 min at room temperature and
mounted on glass slides with DAPI Fluoromount G
(Southern Biotech). Analysis was performed using a TCS
SP5 confocal microscope (Leica).
Histological and immunohistochemical stainings
Sampling, formalin fixation, paraffin embedding, hema-
toxilin and eosin (H&E) staining as well as immuno-
staining with anti-prion protein antibody SAF84
(Caiman Chemical) of murine brain samples has been
described earlier [50]. Immunostaining of shed PrP was
likewise performed in one run using a Benchmark XT
machine (Ventana) to allow for best comparability. In
brief, deparaffinated brain sections were boiled for 1 h in
citrate buffer (CC1 Cell Conditioning Solution, Ventana)
for antigen retrieval and then incubated for 1 h with the
sPrPG228 primary antibody (7 μg/ml; in antibody diluent
solution (Zytomed) with 5% goat serum). Detection with
anti-rabbit secondary antibody (Nichirei Biosciences)
and Ultra View Universal DAB Detection kit (Ventana),
as well as blue counterstaining were performed by the
machine following standardized protocols.
Exosome isolation and nanoparticle tracking analysis
N2a cells were cultured in OptiMEM for 18 h. For the
harvest of extracellular vesicles (here further referred to
as exosomes), cell culture supernatants were first com-
plemented with PI and centrifuged for 10 min at 1000 g
and further at 7500 g for 15 min at 4 °C, followed by fil-
tration through a 22 μm membrane to clear it from dead
cells and debris. Exosomes were then pelleted by ultra-
centrifugation at 100,000 g for 70 min at 4 °C in an Op-
tima L-100 XP using a SW40Ti rotor (Beckman Coulter,
Inc.) and subsequently resuspended in PBS containing
PI. For quantification and characterization, a NanoSight
LM14 (Malvern Instruments) equipped with a 638 nm
laser and a Marlin F033B IRF camera (Allied Vision
Technologies) was used. For each sample, 10 videos of
10 s length were recorded with a camera intensity set-
ting of 16 and analysed to assess average size and con-
centration of exosomes using the batch processing
function of the software. For normalized western blot
analysis, 5 × 1010 exosomes per sample were used.
Statistical analysis
For experiments using mouse brain samples, n refers to
the number of biological samples (i.e. mice) per experi-
mental group. For cell culture-based data, n stands for the
number of independent experiments. Statistical compari-
son of western blot quantifications was performed using
Student’s t-test and significance was considered with p-
values as follows: *p < 0.05, **p < 0.005, ***p < 0.001.
Results
A novel antibody specifically detects shed PrP and reveals
important insight into the ADAM10-mediated shedding of
PrPC in mice and cells
ADAM10 is the relevant sheddase of PrPC releasing a
soluble form (shed PrP, sPrP) from the plasma
membrane [47, 48]. Since membrane-bound full length
(fl) PrPC and its shed form only differ in three amino
acids (murine sequence) and the GPI-anchor, it is hard
to reliably discriminate between both in most ap-
proaches. Based on available sequence information and
the previous identification of the cleavage site for
ADAM10 [47], we therefore generated an antibody spe-
cific for sPrP (sPrPG228) being directed against the newly
generated carboxy-terminus at Glycine 228 (G228) ex-
posed after cleavage (Fig. 1a).
To characterize this antibody in detail, we analyzed
forebrain homogenates of age-matched Prnp0/0 mice (as
negative control), recently described mice with neuron-
specific (CamKIIα-driven) depletion of ADAM10 (A10
cKO; to control for specificity) as well as wild-type litter-
mate controls, and PrPC-overexpressing tga20 mice (as
positive controls) by western blot. As expected,
detection with our new antibody consistently revealed
no signal in Prnp0/0 samples, basal levels in wild-type
mice and strongly increased signal intensity in tga20
mice (Fig. 1b). Though we expected significantly reduced
levels of shed PrP in A10 cKO mice, to our surprise we
could not detect any signal in these samples. Besides
supporting the specificity of the antibody, this indicates
that no other cell types or proteases contribute to this
cleavage in brain. Re-probing the same blot with an anti-
body against fl-PrP revealed an increase in total PrPC
levels in A10 cKO mouse brains (Fig. 1b), a finding that
has been made earlier and can be attributed to the lack
of shedding [50]. Moreover, while this blotting strategy
demonstrated the overlapping banding pattern (as well
as the masking of sPrP signals by excess amounts of fl-
PrP using common PrP antibodies), it also revealed a
small shift in the molecular weight of sPrP correspond-
ing to the lack of three amino acids and the GPI-anchor
(Fig. 1b and Additional file 1). We also investigated the
species specificity of the new antibody using mouse, rat
and rabbit brain samples. As expected for the different
C-terminal PrPC sequences, the sPrPG228 antibody only
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detected sPrP in brain homogenates of mice and rat
(Additional file 2).
Though not being in the focus of this study, we were
also interested in the applicability of the antibody in
morphological analyses and performed immunohisto-
chemical staining of paraffin-embedded mouse brain
sections. As exemplified for the hippocampal area in
Additional file 3, no signal was obtained in a Prnp0/0
mouse, whereas a diffuse staining was found in wild-type
and, with higher intensity, in tga20 brain as could be ex-
pected for a soluble fragment distributed in the brain
parenchyma.
Although, structurally, all three glycoforms of PrPC
can be shed (as demonstrated in tga20 brain (Fig. 1c)), a
strong predominance of the diglycosylated form of sPrP
was obvious in all of our biochemical analyses. To
investigate this in more detail, we analyzed the
glycopattern of sPrP compared to cell-associated fl-PrP
in brain homogenates of wild-type mice (Fig. 1d) and
found a clear shift and a drastic increase in the propor-
tion of diglycosylated sPrP (mean: 97 ± 1%; compared to
60 ± 4% for fl-PrP; n = 3; ±SD) with only little mono- (3
± 1%; fl-PrP: 33 ± 3%) and almost no unglycosylated sPrP
(0.07 ± 0.03%; fl-PrP: 6.8 ± 0.8%).
As a model for downregulation of ADAM10-mediated
cleavage events, we investigated PrP shedding in fore-
brains of mice overexpressing a dominant negative form
of ADAM10 (A10 d.n.) in addition to the endogenous
protease [68] (Fig. 1e). When referring the sPrP to the
respective fl-PrP signal, we found a ~ 50% reduction
(mean sPrP/fl-PrP ratio: 0.51 ± 0.05; n = 4; ±SEM) in
A10 d.n. mice compared to matched controls (set to 1.
00 ± 0.13).
Since for main parts of this study we used N2a cells
transfected with murine versions of PrPC containing the
3F4 tag in the middle of the protein sequence, we first
had to show that this modification does not influence
the shedding event. This is even more important as it is
known, that the course of prion diseases is altered by
this tag [70, 74]. We therefore decided to investigate
shedding in the best possible model, i.e. in PrP3F4 knock-
in (KI) mice expressing levels of 3F4-tagged PrP identi-
cal to PrPC levels in wild-type mice (Additional file 1)
[70]. No significant differences in sPrP levels were ob-
served between controls (set to 1.00 ± 0.23; n = 3; ±SD)
and PrP3F4 KI mice (0.85 ± 0.12) thus ruling out an
impact of this modification on PrP shedding as could be
expected from its intramolecular distance to the
membrane-proximate shedding site.
We next employed the new antibody in cell culture-
based experiments. Given that manipulation of PrPC
shedding may become a therapeutic option in different
pathologies, we investigated how pharmacological
stimulation and inhibition of ADAM10 affect sPrP
production in N2a cells (Fig. 1f,g). Among others, the
stilbenoid resveratrol and the synthetic retinoid
tamibarotene (Am80) have been successfully used to
increase ADAM10-mediated cleavage events [75, 76].
We also found elevated levels of sPrP in supernatants of
N2a cells treated with these substances compared to
solvent-treated controls (Fig. 1f ). In contrast, shedding
was abolished upon treatment with the ADAM10-
selective inhibitor GI254023X (GI) [77]. Of note, upon
re-probing the “supernatant blot” with another PrP anti-
body (POM2), a strong signal was obtained under GI-
treatment indicative of a release of fl-PrP by alternative
routes when shedding is blocked (as discussed later). Fit-
tingly, cell-associated PrPC levels (in lysates) remained
rather unaffected by the different treatments further
supporting existence of compensatory mechanisms
regulating PrPC homeostasis in N2a cells (discussed
later). We also assessed the metalloprotease inhibitors
GM6001 and batimastat (Fig. 1g). These drugs likewise
abolished the shedding of PrPC at the cell surface yet did
not significantly alter production of N1 and C1
fragments resulting from the α-cleavage of PrPC. There
is controversy regarding the involvement of ADAMs in
the α-cleavage (reviewed in [45, 78]). However, due to
the lack of membrane permeability of the inhibitors used
here, this finding cannot count as an argument against
ADAMs as potential “α-PrPases”, given that α-cleavage
is thought to occur mainly within the secretory pathway
[79]. Again, levels of cell-associated fl-PrP did not ap-
pear to be altered by these treatments.
Lastly, consistent with our findings in mouse brain
(Fig. 1d), we also observed a changed glycopattern of
sPrP compared to fl-PrP in N2a cells (Fig. 1h; diglycosy-
lated: 84.2 ± 4.4% (sPrP) vs. 67.4 ± 0.9% (fl-PrP); mono-
glycosylated: 15.6 ± 4.2% (sPrP) vs. 29.6 ± 1.0% (fl-PrP);
unglycosylated: 0.22 ± 0.18% (sPrP) vs. 2.9 ± 0.3% (fl-
PrP); n = 3; ±SD) though relatively more monoglycosy-
lated sPrP is found in N2a cells (15.6 ± 4.2%) than in
brain (3 ± 1%; Fig. 1d). To clarify whether our findings
indicate a real preference for the shedding of diglycosy-
lated PrP or rather reflect the availability of different gly-
coforms at the plasma membrane, we performed cell
surface biotinylation and glycopattern analysis in N2a
cells (Additional file 4). Though relatively more diglyco-
sylated PrP is indeed available at the plasma membrane
(compared to total PrP levels in cell lysates;
Additional file 4B), our data still argues in favor of a
preference for diglycosylated PrP given the strong pre-
dominance of this form among shed PrP (Fig. 1d, h). In
summary, we have generated a sensitive and highly spe-
cific antibody to discriminate between shed and fl-PrP in
mouse brains and cell culture supernatants. ADAM10
on neurons seems to be the dominant (if not exclusive)
PrP sheddase. ADAM10-mediated shedding of PrPC can
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be modulated by various means, and our shedding-
specific antibody is a useful read-out tool for such exper-
iments. Though all glycoforms can in principle be shed,
diglycosylated PrP by far represents the major substrate
for ADAM10.
The glycosylation state impacts on PrP shedding
Glycosylation of PrPC impacts on its biology and role in
prion disease [62, 80–83]. Given the predominance of
diglycosylated sPrP under normal conditions (Fig. 1), we
wondered how shedding would be affected if only
specific glycoforms of PrPC are present in cells. To this
end, we transfected PrPC-depleted N2a cells (PrP-KO;
generated using the TALEN strategy and described
earlier [72]) with either wild-type PrP or PrP glycomu-
tants carrying a mutation in either the first (N180Q mu-
tant; PrP-G1), the second (N196Q mutant; PrP-G2) or
both (N180Q/N196Q mutant; PrP-G3) N-glycosylation
sites and, thus, giving rise to mono- (G1 and G2) or
unglycosylated (G3) PrPC. Using these glycomutants, we
could previously demonstrate a relevant impact of the
N-glycans on the sorting of PrPC in polarized cells [61].
Despite differences in transfection efficiencies, western
blot analysis revealed the typical banding pattern for the
glycomutants as observed for similar mutants in
transgenic mice (Fig. 2a) [83]. Like fl-PrP, the
membrane-attached C1 fragment resulting from α-
cleavage of PrPC also presents with a three-banding
pattern with the diglycosylated C1 overlapping with
unglycosylated fl-PrP. For a better characterization, de-
glycosylation was performed to only obtain unglycosy-
lated fl-PrP and C1 fragment and showed that all
mutants undergo α-cleavage (Fig. 2b). No effect was ob-
served upon treatment of lysates with Endo H indicating
a correct processing of the glycans and trafficking out of
the ER and to the cellular surface for all transfected mu-
tants (Fig. 2c). Immunofluorescence analysis of surface
PrPC further supported a correct biosynthesis and
showed that all mutants are readily expressed at the
plasma membrane (Fig. 2f ) confirming previous results
in polarized MDCK cells [61]. Of note, analysis of sPrP
in media supernatants revealed that not only fl-PrP but
also the truncated C1 fragment can be shed for all glyco-
forms (Fig. 2d; deglycosylation of supernatants for con-
firmation of bands is shown in Fig. 2g). Quantification
(Fig. 2e) of sPrP referred to total PrP (to correct for dif-
ferent transfection efficiencies) showed a moderate de-
crease in sPrP for the monoglycosylated mutants, yet a
significant reduction to ~ 50% was observed for the
unglycosylated PrP-G3 (mean: 0.49 ± 0.11 compared to
PrP-WT set to 1.00 ± 0.04; n = 3; ±SEM). Interestingly,
as indicated by asterisks in Fig. 2a and d, for the ungly-
cosylated PrP-G3 mutant we consistently detected a sig-
nificant difference in the ratio of PrP and C1 between
membrane-associated (fl-PrP: 61%; C1: 39%; ±4.5% SEM;
n = 3) and shed forms (sPrP: 21%; shed C1: 79%; ±6.2%).
This increase in the proportion of C1 (from 39% in ly-
sates to 79% among the shed PrP forms) in the absence
of N-glycans may relate to the longer half-life of C1 at
the plasma membrane and a fast re-internalisation of
unglycosylated fl-PrP [84–86] which seems to be disfa-
vored as a substrate (Fig. 2i). In contrast, for normally
glycosylated PrP-WT, there appeared to be a preference
for the shedding of (diglycosylated) fl-PrP over the
(diglycosylated) C1 fragment when comparing fl-PrP and
C1 ratios in PNGase F digested lysates (Fig. 2b) and
media supernatants (Fig. 2g). This observation prompted
us to investigate a potential influence of the N-terminal
half of PrPC on the membrane-proximate shedding. We
therefore transfected PrP-KO N2a cells with PrP-WT or
with an N-terminally truncated construct (PrP-C1) cor-
responding to the physiological C1 fragment
(Additional file 5). Despite indicating that a preference
for the shedding of diglycosylated forms also exists for
the C1 fragment, shedding of the latter was significantly
reduced compared to fl-PrP in cells transfected with
PrP-WT. Although further analysis are clearly required
and differences might partially result from transient
overexpression and altered surface expression of the
constructs, these findings point to a role of the PrP N-
terminal domain in the C-terminal shedding event.
Thus, the glycosylation state as well as proteolytic trun-
cation seem to affect PrPC shedding.
Shedding is also affected by pharmacological modulation
of PrPC glycosylation
To support our findings obtained with PrP glycomutants
(Fig. 2), we pharmacologically manipulated glycosylation
in wild-type N2a cells. While the antibiotic tunicamycin
(TM) inhibits N-glycosylation, the alkaloid swainsonine
(SWA) is a known inhibitor of the further maturation of
N-linked glycan structures resulting in non-mature
high-mannose glycans. Treatment of cells with TM com-
pletely prevented N-glycosylation of PrPC, whereas
treatment with SWA resulted in a shift in the molecular
weight of diglycosylated PrPC indicating immature
glycosylation (Fig. 3a). Digestion of lysates with Endo H
revealed that SWA (partially) impaired complex
glycosylation as shown by an altered glycopattern
compared to controls (Fig. 3b). Further confirmation for
the TM- and SWA-treatments and the enzymatic degly-
cosylation reactions is presented in a side-by-side com-
parison (Additional file 6). However, it should be noted
that we did not reach a complete deglycosylation in the
case of Endo H-digestion of lysates of SWA-treated cells.
Presence of residual complex glycosylated PrPC suggests
that the incubation with SWA (8 h) was too short or
that Endo H digestion was incomplete. Independent of
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the type of treatment, PrPC was expressed at the
cellular surface (Fig. 3c). Intriguingly, PrPC shedding
was almost completely abolished in cells treated with
TM (mean: 0.07 ± 0.03; n = 3; SEM) and significantly
reduced upon treatment with SWA (0.41 ± 0.10)
compared to untreated controls (set to 1.00 ± 0.12)
(Fig. 3d, e). Even though only little non-mature digly-
cosylated PrPC was present in SWA-treated cells
(Fig. 3b), this fraction seems to be the only relevant
substrate for shedding. Again, these data support our
previous findings (Figs. 1 and 2) showing that digly-
cosylated PrP is the preferential substrate for
Fig. 2 PrP glycosylation mutants are differentially shed. Representative western blot characterization of PrPC depleted N2a cells (PrP-KO) transfected
with wild-type PrP (PrP-WT) or the PrP glycomutants N180Q mutant (PrP-G1), N196Q (PrP-G2) and N180Q/N196Q (PrP-G3) showing the glycopattern in
untreated lysates (a) as well as upon deglycosylation with PNGase F (b). c Digestion of lysates with Endo H does not reveal obvious alterations
compared to the glycopattern in undigested samples (a), proving correct sorting and processing of the glycomutants. The differentially
glycosylated C1 fragments resulting from α-cleavage of PrPC are also detected in A,B and C. Actin was detected as loading control. d
Analysis in precipitated media supernatant using the sPrPG228 Ab reveals that not only PrP but likewise its C1 fragments are shed in PrP-
WT and all glycomutants. e Quantification of PrP shedding. For normalization, intensity of sPrP signals in media was referred to total
amounts of PrP in cell lysates. A trend of reduced shedding is observed for all glycomutants when compared to PrP-WT and a significant
decrease is found for unglycosylated PrP-G3 (n = 3; p = 0.018). f Confocal microscopy of PrP surface staining confirms presence of all glycomutants
at the cell surface (scale bar = 10 μm). g PNGase F digestion of precipitated cell culture supernatant. h For the unglycosylated G3 mutant we
found a significant shift in the C1 to PrP ratio between cell lysates (membrane-bound forms; see asterisk in a) and supernatants (shed
forms; see asterisk in b). Intensity for PrP-C1 in supernatants or lysates was referred to the respective fl-PrP signal. Shed C1 is significantly
increased compared to membrane-bound C1 (n = 3; p = 0.007). i Schematic representation of PrP shedding summarizing the reduced
shedding and the relative preference for C1 in mutants with impaired glycosylation
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ADAM10 at the cell surface and that altered glyco-
sylation influences PrP shedding efficiency.
Membrane anchorage and topology of PrPC determine its
shedding efficiency
An additional modification that influences membrane
topology, biological functions and pathophysiological
roles of the prion protein is the type of membrane
attachment. With PrPC being one of only few GPI-
anchored substrates of ADAM10 [47, 87], we won-
dered how altered attachment and topology at the
membrane would affect its shedding. To this end, we
used mutants of PrPC either comprising a
transmembrane domain instead of the GPI-anchor
(PrP-TM) or carrying the GPI-anchor signal sequence
(and –as a likely consequence– the GPI-anchor [61]
(Puig et al. submitted)) of Thy-1, a protein described
to reside in the dense cores of detergent-resistant
membranes (herein referred to as lipid rafts) [88].
Whereas interaction between ADAM10 and PrPC is
thought to occur at the interface between lipid rafts
and non-raft regions (Fig. 4a), previous studies have
shown that PrP-TM is relocated outside of rafts and
turned signaling-incompetent [38, 63, 89] while
PrPGPIThy-1 remains in rafts yet therein shows a
different localization than PrP-WT [61] (Puig et al.
submitted).
Immunofluorescent stainings of non-permeabilized
cells showed surface expression (Fig. 4b) while west-
ern blot analysis revealed comparable expression of
all constructs transfected into PrP-KO N2a cells
(Fig. 4c). Deglycosylation of samples showed that all
PrP mutants are subject to α-cleavage and con-
firmed an increase in molecular weight for PrP-TM
due to its transmembrane domain (Fig. 4d). No al-
terations in the banding pattern were observed upon
treatment with Endo H indicating correct glycosyla-
tion and –again– surface transport of all mutants
(Fig. 4e). Lack of signal in the media for PrP-TM
upon incubation of cells with PI-PLC proved the ab-
sence of a GPI-anchor and its attachment via a
transmembrane domain (Fig. 4f ).
Of note, despite a conserved shedding site in all con-
structs, shedding was completely abolished for PrP-TM
(mean: 0 ± 0.02; n = 3; SEM) and significantly reduced
for PrPGPIThy-1 (0.33 ± 0.06) compared to PrP-WT (set to
1.00 ± 0.05) (Fig. 4g,h). In conclusion, altered membrane
attachment and, hence, changed membrane localization
severely impact on PrPC shedding.
Shedding is part of a compensatory cellular network
regulating PrPC homeostasis
As already shown in Fig. 1f, we consistently ob-
served an increased cellular release of PrP via alter-
native routes whenever the proteolytic shedding was
Fig. 3 Pharmacological manipulation of N-glycosylation alters PrP shedding. a Representative western blot analysis of wild-type N2a cells either
left untreated or treated with DMSO (as a solvent control), 2.5 μg/ml tunicamycin (TM) or 5 μg/ml swainsonine (SWA). For TM only unglycosylated
PrP is detected. The SWA-treated sample reveals a slight downwards shift for diglycosylated PrP compared to DMSO- and untreated samples. b
Endo H digestion further demonstrates an altered glycopattern for SWA-treated cells indicating that correct maturation to complex N-glycans was
(at least partially) impaired. Actin served as loading control. c Staining on non-permeabilized cells demonstrating that, in all conditions, PrPC is
sufficiently expressed at the plasma membrane. d Representative western blot showing shed PrP in corresponding (precipitated) media supernatants.
e Quantification of shedding efficiency (measured as the ratio of shed PrP in supernatants to fl-PrP in respective lysates) showing almost abolished
shedding in TM-treated (n = 3; p = 0.002) and impaired shedding in SWA-treated cells (n = 3; p = 0.020)
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impaired (e.g. by inhibition of ADAM10 with GI;
Fig. 5a). Since PrPC is released via microvesicles (e.g.
exosomes [72, 90, 91]), we wondered whether this
mechanism could compensate for abolished shedding.
Inhibition of ADAM10 with GI resulted in a significant
rise of exosome release (mean: 1.48 ± 0.09; compared to
controls set to 1.00 ± 0.09; n = 4; SEM; Fig. 5b) without
affecting the typical size of these vesicles (mean: 128 ±
12 nm; compared to controls 115 ± 2 nm; n = 4; SEM; Fig.
5c; details for characterization of exosomes are shown in
Additional file 7). When amounts of exosomes were
normalized, we found more than a twofold increase in their
average PrPC load upon GI treatment (2.12 ± 0.08; compared
to controls set to 1.00 ± 0.08; n = 3; SEM; Fig. 5d,e). PrPC
levels in the corresponding cells were only moderately, yet
significantly increased (1.40 ± 0.07; compared to controls set
to 1.00 ± 0.07; n = 3; SEM; Fig. 5d,f). Thus, as a consequence
of impaired shedding, more PrPC is packed into
exosomes and more exosomes are released by N2a
cells. Interestingly, such an alternative release of PrPC
Fig. 4 Membrane attachment and topology of PrPC impact on its shedding. a Schematic representation of the expected subdomain localization
of transmembrane PrP (PrP-TM; outside of lipid rafts) and PrP with an altered GPI-anchor signal sequence (PrPGPI-Thy1; in the core of lipid rafts)
compared to wild-type PrP (PrP-WT; in the periphery of lipid rafts) at the plasma membrane. b Confocal microscopy showing that all PrP constructs are
expressed and present at the cell surface upon transfection into PrP-KO N2a cells. c,d,e Representative western blots showing comparable expression
of the constructs in lysates (c), revealing presence of both fl-PrP and C1 upon deglycosylation (d), and indicating correct processing and sorting as
there is no altered glycopattern upon digestion of samples with Endo H (e). f Biochemical analysis upon incubation of cells with phospholipase
C (PI-PLC) to cleave GPI-anchor structures. For PrP-WT, a reduction in cell-associated fl-PrP is accompanied by appearance of PrP in supernatants.
Lack of this release in the case of PrP-TM confirms absence of a GPI-anchor and supports membrane attachment via a transmembrane domain. g
Representative western blot analysis using the sPrPG228 Ab reveals lack of shed PrP for PrP-TM and reduced shedding in cells expressing
PrPGPI-Thy1 compared to PrP-WT. Quantification of the ratio of shed PrP (g) referred to fl-PrP (c) is shown in H (PrP-WT was set to one;
p = 0.00005 for PrP-TM to PrP-WT; p = 0.001 for PrPGPI-Thy1 to PrP-WT; n = 3)
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was not observed in murine fibroblasts (MEF) lacking
ADAM10 (Additional file 8) [71] which instead accumulated
PrPC to 3-fold the amount of wild-type MEFs (ADAM10 KO:
3.07 ± 0.12; WT set to 1.00 ± 0.12; n = 8; SEM). This may in-
dicate that not all cell types possess the compensatory ma-
chinery ensuring PrPC release and membrane homeostasis.
Fig. 5 Shedding plays a key role in PrPC homeostasis of a cell. a Representative western blot of N2a cells treated with the ADAM10 inhibitor
GI254023X (GI; or DMSO as control). No sPrP is detected upon GI treatment yet re-probing the blot with POM2 Ab indicates release of PrP by
other routes. b Quantification of relative amounts and (c) average size of exosomes released by N2a cells upon treatment with GI. Nanoparticle
tracking analysis shows a significant increase in exosomal release (n = 4; p = 0.011) while the size of exosomes is not altered (n = 4). d After GI or
DMSO treatment, cell lysates (Lys) and normalized amounts of exosomes (Exo) were analysed by western blot. Note that only mature ADAM10 is
sorted into exosomes. Quantifications of relative exosomal PrPC load (e; n = 3; p = 0.0006) and PrPC levels in cell lysates (f; n = 3; p = 0.019) upon
GI (or DMSO) treatment. PrPC signals were referred to flotillin signal for quantification. g Representative western blot of N2a cells treated with
lysosomal inhibitor Leupeptin (Leupt.) or left untreated (untr.) showing levels of sAPPα, sPrP and released PrP in media supernatants as well as
cell-associated fl-PrP and cytosolic proteins β-catenin, β-tubulin and β-actin in lysates. Quantification shows no alterations of relative PrP levels in
lysates (h; n = 3) yet a significant increase in PrP shedding (i; n = 3; p = 0.018) caused by lysosomal inhibition. jWestern blot analysis of brain homogenates
of sortillin-1-deficient (Sort1 KO) and control mice (Sort1 WT). Sort1 KO mice present with elevated levels of both sPrP and fl-PrP. Quantification of relative
levels of sPrP (referred to actin) is shown (n = 4; p = 0.0103). k Schematic drawing summarizing three compensatory arms in the regulation of cellular PrP
levels: ADAM10-mediated shedding (orange arrow), exosomal release (green arrow) and lysosomal targeting and degradation (blue arrow). Scheme makes
no claim to completeness as other important factors regulating PrPC levels, such as transcriptional/translational control, are not depicted here
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Finally, we investigated how degradation, as a third as-
pect involved in cellular PrPC homeostasis, influences
PrPC shedding. We blocked lysosomal degradation by
treatment of N2a cells with leupeptin. As expected,
cytosolic proteins (e.g. β-actin, β-tubulin, β-catenin)
known to be degraded by the proteasome rather than in
lysosomes were not accumulated (Fig. 5g). Instead, in-
creased secretion of sAPPα, the proteolytic fragment of
APP, indicated successful lysosomal inhibition (Fig. 5g).
Of note, cell-associated PrPC levels remained rather
stable despite this treatment (Leupt.: 0.97 ± 0.05; untr.
Cells set to 1.00 ± 0.05; n = 3; SEM; Fig. 5g,h) yet
shedding of PrPC was significantly increased (Leupt.:
2.31 ± 0.24; untr. Cells set to 1.00 ± 0.24; n = 3; SEM;
Fig. 5g,i). No obvious differences in alternatively
released PrP (Fig. 5g) suggests that, in this condition,
shedding is the main contributor avoiding increased
cellular PrPC levels.
Impaired lysosomal degradation and increased PrPC
levels have recently been shown in mice lacking the
sorting receptor sortilin-1 [69]. As a consequence of hin-
dered transport to lysosomes, these mice had shown in-
creased PrPSc conversion and shortened survival when
infected with prions. Given the increase in shedding
upon lysosomal inhibition with leupeptin in cells shown
before, we asked whether shedding of PrPC is likewise
affected by the impaired degradation due to lack of
sortilin-dependent transport in vivo. In fact, we found
an approximately 2-fold increase for sPrP in sortilin1-
deficient mice compared to controls (Sort1 KO: 1.85 ± 0.
32; Sort1 WT set to 1.00 ± 0.09; n = 4; SD; Fig. 5j). Ra-
ther than from up-regulation of sheddase activity, this
increase seems to result from elevated cellular PrPC
levels caused by impaired degradation (Additional file 9).
Nevertheless, this demonstrates the capability of
ADAM10 to release increased amounts of substrate.
In summary, these data suggest ADAM10-mediated
shedding as a relevant factor regulating PrPC levels.
Shedding, exosomal release and degradation of PrPC
may be interconnected mechanisms that act in a
compensatory manner ensuring PrPC homeostasis and
allowing –if at all– only subtle changes thereof.
Discussion
Evolutionary conserved proteolytic processing of the
prion protein has been described a quarter of a century
ago [92–94] (reviewed in [28]). However, we are just be-
ginning to appreciate the physiological and pathological
relevance of such cleavage events, which is partially due
to technical difficulties in reliable detection of the re-
spective fragments. We here present a novel antibody
that detects shed PrP with high specificity and sensitivity
in different applications. Despite the existence of several
valuable antibodies against various epitopes in PrPC (e.g.
the POM antibodies used in this study [73]), until now it
has only been possible to detect shed PrP upon rather
labor-intensive and error-prone immunoprecipitation
from or strong concentration of cell culture superna-
tants [47, 48]. And even that way, contribution of PrPC
released from cells by other routes (e.g. via exosomes)
[91] to respective signals has to be considered. In tissue
samples it has so far been impossible to specifically
detect shed PrP due to the excess amounts of cell- or
extracellular vesicle-associated fl-PrPC of similar
molecular weight masking any signal coming from the
fraction of proteolytically shed PrP. This resulted in a
lack of in vivo insight. These problems have been
overcome and novel findings have been made with the
new antibody.
Despite confirming antibody specificity, the absence of
shed PrP in forebrain homogenates from mice with a de-
pletion of ADAM10 in forebrain neurons to our surprise
indicates that, at least under physiological conditions, no
other cell types in the brain contribute to shedding in a
detectable manner. It also questions a shedding of (neur-
onal) PrPC in trans (e.g. by adjacent glia cells not
depleted of the protease), a mechanism that has been
shown for the ADAM10 substrate ephrin in HEK cells
[95]. Our findings of abolished shedding in the absence
of ADAM10 or upon pharmacological inhibition of
ADAM10 also indicate that no other protease
compensates for these manipulations in vitro or in vivo.
Further support comes from mice coexpressing
dominant negative ADAM10 with endogenous
ADAM10, where we found a comparably strong (~ 50%)
reduction in PrP shedding. Instead, previous western
blot analyses of sAPPα in ADAM10 d.n. mice only
showed a reduction of ~ 25% [96, 97] hinting at the
known contribution of ADAM17/TACE in the cleavage
of APP [98]. It should be considered that cleavage by
another protease at a slightly different cleavage site
would prevent detection with our antibody. However,
our previous results obtained by pull-down of shed PrP
from media of primary ADAM10 knockout neurons
with classical PrP antibodies [48], together with a recent
biophysical study [31], and the lack of any other re-
ported candidate protease linked to the membrane-
proximate shedding of PrPC, support the view of
ADAM10 as the only relevant sheddase of PrPC. This is
in clear contrast to the cleavage of other typical
ADAM10 substrates such as APP, which –as mentioned
above– to varying degrees and dependent on the
experimental paradigm, can also be processed by other
proteases [71, 99–101].
Our analysis suggests that diglycosylated PrPC is the
preferred glycoform to be shed by ADAM10, whereas
mono- and especially unglycosylated forms seem to be
relatively disfavored. Our data also indicates that this
Linsenmeier et al. Molecular Neurodegeneration  (2018) 13:18 Page 12 of 17
finding not simply results from differences in the
availability of individual glycoforms as substrates at the
plasma membrane under normal conditions (our
transfected glycomutants as well as PrPC in cells treated
with TM or SWA were by all means localized at the
surface). An alternative explanation could be that shed
diglycosylated PrP is more protected than the other shed
forms from potential cellular uptake and degradation
and, thus, more abundant. In any case, among all soluble
PrPC fragments released from the cell by the proteolytic
cleavages described to date, shed PrP is the only one
that is glycosylated. As discussed earlier [28] this may
well impact its binding affinities to both, toxic
extracellular oligomers as well as physiological binding
partners (e.g. surface signaling receptors), and thus
define its specific biological functions. Moreover, by the
predominantly diglycosylated state, physiologically shed
PrP clearly differs from anchorless, mainly unglycosylated
PrP of transgenic mice used in several seminal prion
inoculation studies in the past [54, 102–104]. This
difference has to be considered and, in the context of prion
diseases, might explain why transgenic anchorless PrP
efficiently converts to PrPSc and can even spontaneously
form prions [54, 103], whereas shed PrP rather seems to
block PrPSc formation in mice [50]. Fittingly, the N-glycans
are known to influence transmissibility and conversion to
PrPSc [62, 80–83].
Altered shedding efficiency for different glycoforms,
however, might in part also be caused by a different sort-
ing given that the glycans have a significant impact on
the polarized trafficking of PrPC in MDCK cells [61].
Despite a role for the N-glycans, we also demonstrated
that changes in the type of membrane anchorage and, as
a likely consequence, altered membrane topology affects
shedding. Shifting PrPC outside of rafts by addition of a
transmembrane domain [63, 89] completely abolished
the shedding while the assumed re-localization of PrPC
within lipid rafts via exchange of the GPI-anchor signal
sequence [61, 88] reduced shedding to ~ 30% in N2a
cells. The latter is in good agreement with unpublished
data obtained in transgenic mice expressing the same
PrPGPIThy-1 construct (Puig et al., submitted). Instead of
changing the anchorage of the substrate as done here,
others have changed membrane attachment of the
protease [105]. Lipid raft targeting of ADAM10 by
addition of a GPI-anchor in that study severely affected
APP processing. Unfortunately, processing of PrPC was
not investigated there.
Since ADAM10 is mainly located outside of lipid rafts
[105, 106], whereas PrPC is a resident of these
microdomains, transient interaction between protease
and substrate (presumably regulated by accessory
proteins such as tetraspanins [107–109]) and cleavage is
thought to occur at the periphery of rafts. This
molecular get-together might further be supported by
the capacity of PrPC to leave and re-enter lipid rafts in a
constitutive manner [85, 110, 111]. Our findings also
suggest an impact of the flexible N-terminal part of PrPC
on the shedding efficiency. Whether this unanticipated
influence is due to sterical aspects or rather reflects the
role of regulatory binding partners known to especially
interact with the N-terminal half of PrPC [5, 27, 112],
deserves further investigations.
Our data indicate that shedding is a relevant mechan-
ism embedded in a compensatory machinery ensuring
homeostasis of PrPC. In neurons and neuronal cells, this
system (involving proteolytic and exosomal release as
well as trafficking to lysosomes) seems to ensure that
cell-associated PrPC levels are kept stable or –at most–
increase twofold upon perturbation (as indicated in
some experiments of this study and observed in neurons
or mice lacking the sheddase ADAM10 [48, 50] or the
transport factor sortilin-1 [69]). Interestingly, a recent
study showed that exosomal release is controlled by
PrPC membrane levels [113]. Though clearly requiring
further investigation, it might be speculated that other
cell types, such as fibroblasts studied here, do not
possess the system to compensate for such perturbation
in one of the mechanisms discussed above, and
consequently accumulate PrPC to higher levels.
Manipulation of PrPC shedding is feasible and might
be of therapeutic interest. Despite the challenge by
possible side effects due to the broad spectrum of
ADAM10 substrates, one obvious question then is into
which direction to modify PrPC shedding [87, 114].
With regard to neurodegenerative proteinopathies,
such as Alzheimer’s or prion diseases, stimulation of this
cleavage will likely be beneficial. First, it reduces PrPC
levels at the cell surface and may thereby lower
neurotoxicity. Moreover, several studies showed that
soluble PrP targets toxic oligomers and fibrils in the
extracellular space [55–58, 115]. In prion diseases,
shedding efficiency inversely correlates with PrPSc
formation [50, 52]. Notably, resveratrol, the drug that
was used here to stimulate shedding, reduced PrPSc
formation and prion infectivity in a recent study [116].
Whether this anti-prion efficacy is indeed related to
shedding, remains to be investigated. Besides proteino-
pathies, positive effects of stimulated shedding can also
be expected given the potential role of this fragment in
neurite outgrowth [13, 14] and neuroprotection [15, 49].
In that way, the role of shed PrP is reminiscent of
sAPPα, the APP-derived fragment also generated by
ADAM10 [117].
Other pathological conditions, in contrast, may rather
require inhibition of PrPC shedding: it is intriguing that
both, ADAM10 [118, 119] and PrPC, have been linked
with immune signaling and chronic inflammatory
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processes [120, 121] as well as with tumorigenesis and
cancer progression [122–124], where expression levels of
these two proteins generally correlate with poor
prognosis. Though this could well be unrelated co-
incidence, it might also be speculated that these patho-
physiological roles are partially related to the production
of shed PrP. Of note, it is precisely shed PrP that was
causally linked with chronic inflammatory neuropathol-
ogy in HIV patients [60] and development of tumours in
the central nervous system [59] in two recent studies.
This further supports the relevance of shed PrP in differ-
ent pathophysiological conditions and highlights the
need for further studies on the ADAM10-mediated
shedding of PrPC.
Conclusion
Proteolytic shedding of the prion protein has most re-
cently attracted scientific interest with regard to di-
verse pathological conditions affecting the brain.
Using a novel antibody for the specific detection of
shed PrP, we demonstrated structural and regulatory
aspects influencing this cleavage and show that it can
- in principle - be pharmacologically manipulated.
The latter, together with the rather ubiquitous expres-
sion of PrPC in several tissues and cell lines, as well
as the lack of compensation by other proteases
discussed above, also turns (i) PrPC into an ideal
“control” substrate, (ii) assessment of PrPC shedding
into a reliable “read out”, and (iii) our antibody into a
valuable tool for any future studies investigating
ADAM10-mediated cleavages and their pharmaco-
logical accessibility. With direct regard to the shed-
ding of PrPC, both, therapeutic stimulation as well as
inhibition, may be conceivable depending on the
pathological context.
Additional files
Additional file 1: (.jpg) The 3F4-tag in PrPC does not alter the ADAM10-
mediated shedding. Western blot analysis of forebrain homogenates
comparing PrPC shedding between mice expressing endogenous wild-
type PrPC (PrPCWT) and knock-in mice expressing 3F4-tagged PrPC
instead (PrP3F4KI). Quantification was done by referring the sPrP signal to
the respective fl-PrP signal (POM2 Ab) of the re-probed blot and is shown
on the right (n = 3). As in other parts of this study, forebrain homogenates
of Prnp0/0, ADAM10 cKO and tga20 mice served as specificity controls. The
position of air bubbles on the membrane (indicated by arrows) further
supports the slight molecular weight shift between sPrP and fl-PrP
described in Fig. 1b. To prove genotypes of PrPCWT and PrP3F4KI
mice, in a parallel blot shown below, PrPC was first detected with an
antibody directed against the 3F4 epitope and re-probed with POM2.
(JPEG 225 kb)
Additional file 2: (.jpg) Species specificity of the sPrPG228 antibody. (A)
Comparison of the C-terminal amino acid sequence of PrPC in mouse
(Mus musculus), rat (Rattus norvegicus) and rabbit (Oryctolagus cuniculus)
(source: www.uniprot.org). “NH2-…-” indicates the N-terminal direction,
“-GPI” the C-terminal GPI-anchor attachment site. Asterisks indicate
position of ADAM10-mediated shedding in mice and rats with Gly228
representing the new C-terminus of shed PrP. Note the sequence difference
compared with rabbit PrPC. (B) Western blot analysis of forebrain
homogenates from different murine models (tga20, Prnp0/0, wild-type
(C57BL/6)) as well as from rat and rabbit. As expected for its epitope, the
sPrPG228 antibody detects sPrP in mouse (tga20 and wild-type) and rat,
whereas the brain sample of rabbit only presents an immunoglobulin light
chain (rb Ig-LC) signal at 25 kDa resulting from the anti-rabbit secondary
antibody used for detection. Re-probing the blot with POM2 antibody reveals
expression levels of PrPC. (JPEG 388 kb)
Additional file 3: (.jpg) Use of the sPrPG228 antibody for immunohistochemical
stainings. Sagittal brain sections of a Prnp0/0, a wild-type (C57BL/6)
and a tga20 mouse stained with hematoxilin/eosin (H&E), an antibody
against total PrPC (SAF84), or the sPrP Ab showing the hippocampus
(Hc) and parts of cortical areas (Cx) in overviews. Magnifications are
shown for the corpus callosum and CA1 region (upper insets) as well
as for the dentate gyros (DG) and CA3 region (lower insets) of the
hippocampus. With the sPrPG228 Ab, a diffuse brownish staining of
the brain parenchyma is seen for wild-type and tga20 whereas Prnp0/
0 brain only shows blue counterstaining. Comparison with the SAF84
staining reveals that levels of shed PrP correlate with overall PrPC
expression. Scale bars represent 100 μm. (JPEG 1948 kb)
Additional file 4: (.jpg) Differences in the glycopattern between total
and cell surface PrPC in N2a cells. (A) Western blot analysis and (B)
densitometric quantification of glycoform proportions of total (cell
lysates) versus cell surface fl-PrP (biotinylated samples) using POM2
antibody for detection. Absence of actin and almost exclusive expression of
mature ADAM10 (with almost no premature ADAM10) in the biotinylated
samples confirm technical soundness of the assay (the upwards shift of
ADAM10 in gel likely results from the assay protocol). Quantification reveals
that the fraction of diglycosylated PrP at the cell surface is increased
compared to total PrP in cell lysates (diglycosylated: 68.0 ± 0.7% (surface PrP)
vs. 55.1 ± 2.4% (total PrP); monoglycosylated: 23.5 ± 0.8% (surface PrP) vs.
29.3 ± 0.6% (total PrP); unglycosylated: 8.5 ± 0.2% (surface PrP) vs. 15.5 ± 1.9%
(total PrP); n = 3; ±SD). (JPEG 610 kb)
Additional file 5: (.jpg) Preference for the shedding of fl-PrP over truncated
C1 fragment indicates a role of the N-terminal part of PrPC. Western blot
analysis of PrP-KO N2a cells transfected with PrP-WT or N-terminally truncated
PrP-C1 (corresponding to physiological C1 fragment). Analysis of cell lysates
(on the left) reveals N-glycosylation and comparable expression levels for both
constructs. Actin served as loading control. Enzymatic deglycosylation
(PNGase F) was performed and samples run on a parallel blot to confirm
identity of constructs. POM1 antibody was used for detection of PrPC in
lysates. Corresponding cell culture supernatants were precipitated and run
on a parallel blot (on the right) and shed PrP forms were detected with
sPrPG228 antibody. Released sAPPα was detected as loading control for
supernatants. Signal intensities of shed PrP forms (sPrPG228 Ab) were referred
to total PrP signal intensities in lysates (POM1) and quantification reveals a
significantly reduced shedding for PrP-C1 (relative ratio shed/total
PrP: 0.12 ± 0.03) compared to (full-length) PrP-WT (set to 1.00 ± 0.11;
p = 0.0017; n = 3; ±SEM). (JPEG 799 kb)
Additional file 6: (.jpg) Side-by-side comparison of SWA and TM
treatments and enzymatic deglycosylation reactions. Western blot
of untreated (untr.), SWA- or TM-treated N2a cells showing lysates
without (−) or with (+) enzymatic treatment for differential deglycosylation
(Endo H or PNGase F). As also shown in Fig. 3a and b, TM-treatment causes
a complete inhibition of PrP glycosylation, whereas SWA-treatment results
in a shift in the banding pattern (compared to untreated cells) and (at least
partial) Endo H sensitivity due to inhibition of complex glycosylation.
Changes in the glycopattern and running behaviour support the
functioning of our enzymatic deglycosylation protocols also performed for
the experiments shown in Figs. 2, 3 and 4. Actin is shown as a loading
control. (JPEG 221 kb)
Additional file 7: (.jpg) Exosome characterization using the NanoSight
system. Representative experiment showing the raw data of 10 serial
measures (upper curves) and the averaged data (lower curves) derived
from media supernatants of DMSO- or GI254023X (GI)-treated N2a cells.
X-axis: size (nm); Y-axis: concentration (E6 particles/ml). Blue numbers at
the tips of curves represent mean sizes. (JPEG 348 kb)
Linsenmeier et al. Molecular Neurodegeneration  (2018) 13:18 Page 14 of 17
Additional file 8: (.jpg) Embryonic fibroblasts (MEF) of ADAM10
knockout mice accumulate PrPC. Representative western blot of media
supernatants and lysates of wild-type (WT) and ADAM10 KO MEF. Lack of
shedding and no increased compensatory release of PrP is observed in
ADAM10 KO cells. ADAM10 is shown in lysates as a proof of genotypes.
Increased levels of PrPC are found in lysates and quantified by referring
to β-actin (n = 8; p = 0.00005). (JPEG 131 kb)
Additional file 9: (.jpg) Quantification of fl-PrP levels and ratio of sPrP/fl-
PrP in Sort1 knockout mice. These quantifications refer to main Fig. 5j. (A)
Increased amounts of fl-PrP are found in brains of Sort1 KO mice (2.11 ±
0.23; p = 0.0004; n = 4) compared to controls (WT set to 1.00 ± 0.21; SD).
Actin served as loading control and for reference in densitometric
quantification. (B) No significant differences are detected in the ratio
of sPrP to fl-PrP between Sort1 KO mouse brains (0.85 ± 0.07, p =
0.128; n = 4) and controls (WT set to 1.00 ± 0.14). (JPEG 229 kb)
Abbreviations
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